Crypto World

Vertex Stock Rockets On Sionna Therapeutics’ Surprise Cystic Fibrosis Flop

Published

on

Vertex stock surged Monday after its competitor, Sionna Therapeutics (SION), missed the mark for its highly anticipated cystic fibrosis treatment. Sionna’s drug, SION-719, lowered sweat chloride by 1 millimole per liter, on average and compared to a placebo, when added to Vertex Pharmaceuticals’ (VRTX) Trikafta. Measuring chloride, or salt, in sweat is the gold standard for diagnosing cystic fibrosis, a…

Copyright ©2026 Investor’s Business Daily, LLC. All rights reserved. 87990cbe856818d5eddac44c7b1cdeb8

Source link

You must be logged in to post a comment Login

Leave a Reply

Cancel reply

Trending

Exit mobile version